RELEASES DETAILS

Regend Therapeutics’ Lung Regeneration Clinical Program Receives Grade A Evaluation from China’s National Health Commission

Recently, the General Office of the National Health Commission of the People's Republic of China issued the Notice on Work Arrangements for the Filing of Stem Cell and Somatic Cell Clinical Research (Guo Wei Ban Ke Jiao Han [2026] No. 64, the “Circular 64”), and released the grading evaluation results for 153 stem cell clinical research projects as of December 31, 2024.

Among these, the clinical study titled “Autologous Bronchial Basal Cell Therapy for Interstitial Lung Disease”, jointly led by Regend Therapeutics and Shanghai East Hospital (East Hospital, Tongji University), was awarded the highest rating of Grade A and successfully completed. Only 14 projects nationwide received this distinction. This recognition reflects the project’s high standards in scientific rigor, regulatory compliance, and clinical value, and supports its continued advancement toward clinical translation.

National Evaluation Results and Policy Implications

In this nationwide assessment, a total of 14 projects were rated Grade A across 12 medical institutions, while 60 were rated Grade B, 74 Grade C, and 5 Grade D.

According to Circular 64, a total of 47 ongoing projects rated Grade A or B (excluding completed or terminated studies) have been included in a proposed direct filing list. Upon implementation of the updated regulatory framework, these projects will be eligible for streamlined filing through a new information system, allowing them to advance more efficiently into clinical translation and potential industrial application.

Further, under the Regulation on the Administration of Clinical Research and Translational Application of New Biomedical Technologies (the “Regulation 818”), which will take effect on May 1, 2026, Grade A projects are expected to be among the first eligible to proceed toward clinical research and clinical application, providing important policy support for the translation of stem cell technologies from laboratory research into clinical use.

Clinical Study Overview and Findings

The jointly conducted study has been successfully completed. It focuses on interstitial lung disease (ILD), a condition with significant unmet clinical need, and evaluates an innovative therapeutic approach using autologous bronchial basal cell transplantation.

The study systematically assessed safety, efficacy, and mechanism of action. Clinical observations indicated that, during a follow-up period of 3 to 6 months, transplanted cells demonstrated in vivo proliferation, migration, and differentiation, contributing to the repair of damaged lung tissue.

Improvements were observed in key clinical indicators, including:

  • Diffusing capacity for carbon monoxide (DLCO)
  • Six-minute walk distance (6MWD)

In addition, chest CT imaging showed signs consistent with structural repair in affected lung regions. These findings provide clinical observations supporting the therapeutic potential of this regenerative approach.

Expanded Research Across Multiple Indications

In parallel, the research team has conducted additional exploratory studies, including:

  • Autologous bronchial basal cell transplantation for bronchiectasis
  • Exploratory clinical research in chronic obstructive pulmonary disease (COPD)

These studies further expand the potential applications of autologous bronchial basal cell therapy across multiple respiratory diseases and may provide new treatment options for patients with difficult-to-treat pulmonary conditions.

Significance of the Grade A Recognition

The Grade A evaluation by the National Health Commission represents strong recognition of the project’s scientific quality, regulatory compliance, and clinical relevance.

As a high-quality stem cell clinical research program, the project may benefit from a favorable regulatory pathway, supporting accelerated clinical translation and future development. This milestone also reflects continued progress in the standardization and high-quality development of stem cell translational medicine in China.